NASDAQ: INBSIntelligent Bio Solutions Inc Stock
$1.39+0.08 (+6.11%)
Updated Jan 17, 2025
INBS Price
$1.39
Fair Value Price
N/A
Market Cap
$6.10M
52 Week Low
$1.00
52 Week High
$11.70
P/E
-0.35x
P/B
1x
P/S
1.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.63M
Earnings
-$10.42M
Gross Margin
54.6%
Operating Margin
-282.86%
Profit Margin
-287.1%
Debt to Equity
0.95
Operating Cash Flow
-$11M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INBS Overview
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INBS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
F
Momentum
C
Sentiment
C
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important INBS news, forecast changes, insider trades & much more!
INBS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INBS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INBS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INBS is good value based on its book value relative to its share price (1x), compared to the US Medical Devices industry average (4.13x)
P/B vs Industry Valuation
INBS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INBS due diligence checks available for Premium users.
Valuation
INBS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.35x
Industry
38.79x
Market
30.45x
INBS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1x
Industry
4.13x
INBS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INBS's financial health
Profit margin
Revenue
$998.4k
Net Income
-$2.7M
Profit Margin
-269%
INBS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INBS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.7M
Liabilities
$5.8M
Debt to equity
0.95
INBS's short-term assets ($6.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INBS's short-term assets ($6.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INBS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
$0.0
Financing
$42.5k
INBS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INBS vs Medical Device Stocks
Intelligent Bio Solutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.